Penn School of Medicine researchers honored for their work on schizophrenia and depression

July 16, 2004

(Philadelphia, PA) - The National Alliance for Research on Schizophrenia and Depression (NARSAD) has awarded $260,000 to three researchers at the University of Pennsylvania School of Medicine to study causes and treatments for mental illness. NARSAD is the largest donor-supported organization in the world devoted exclusively to funding scientific research on psychiatric disorders.

Wade Berrettini, MD, PhD, Professor of Psychiatry and Irwin Lucki, PhD, Professor of Psychiatry - were each honored with a one-year, $100,000 Distinguished Investigator Award that provides support for experienced investigators. Monica Gonzalez, PhD, a Research Associate in the Department of Psychiatry, earned a two-year, $60,000 Young Investigator Award - which is given to the most promising young scientists conducting research in the area of psychiatric brain disorders. NARSAD's president, Constance E. Lieber, says she is "proud to continue to support the efforts of University of Pennsylvania School of Medicine scientists."

The following Penn projects are being supported by the 2004 NARSAD grants:The scientific leadership of NARSAD, the Scientific Council, reviewed over 1,000 grant applications to select these current awards. The Council includes among its membership three Nobel Prize winners, the present and four former directors of the National Institute of Mental Health, and many of the most distinguished leaders in psychiatric research in the major universities and medical centers around the world.

NARSAD's Young Investigator Award Program provides support for the most promising young scientists conducting neurobiological research. Basic and/or clinical investigators are supported, but research must be relevant to schizophrenia, major affective disorders, or other serious mental illnesses.

NARSAD's Distinguished Investigator Award Program provides support for experienced investigators (full professor or equivalent) conducting neurobiological research. Areas of particular interest to the Scientific Council include patient populations with unique or unusual characteristics and innovative projects that might not otherwise receive funding.
Editor's Note
You may also find this news release online at

PENN Medicine
PENN Medicine is a $2.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation's first integrated academic health system).

Penn's School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System consists of four hospitals (including its flagship Hospital of the University of Pennsylvania, consistently rated one of the nation's "Honor Roll" hospitals by U.S. News & World Report), a faculty practice plan, a primary-care provider network, three multispecialty satellite facilities, and home health care and hospice.

The National Alliance for Research on Schizophrenia and Depression (NARSAD) is a private, not-for-profit public charity 501 (c)(3) organized for the purpose of raising and distributing funds for scientific research in the causes, cures, treatments, and prevention of severe psychiatric brain disorders, such as schizophrenia and depression.

In 17 years, NARSAD has awarded $157.3 million to fund 2,364 grants to 1,883 scientists at 321 universities and medical research institutions.

University of Pennsylvania School of Medicine

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to